WINTON GROUP Ltd Has $1.52 Million Stock Holdings in Roivant Sciences Ltd. $ROIV

WINTON GROUP Ltd trimmed its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 28.8% during the second quarter, Holdings Channel reports. The firm owned 43,031 shares of the company’s stock after selling 17,426 shares during the quarter. WINTON GROUP Ltd’s holdings in Roivant Sciences were worth $1,523,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Roivant Sciences by 4,212.2% during the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock worth $672,448,000 after purchasing an additional 18,560,434 shares during the period. Morgan Stanley raised its stake in Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares during the last quarter. Norges Bank acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $112,750,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $76,272,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Trading Down 0.3%

Roivant Sciences stock opened at $40.82 on Friday. Roivant Sciences Ltd. has a 12 month low of $13.81 and a 12 month high of $42.50. The stock’s 50 day moving average is $35.79 and its 200-day moving average is $31.62. The company has a market capitalization of $29.49 billion, a price-to-earnings ratio of -77.02 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, equities research analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Citigroup boosted their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Jefferies Financial Group raised their price target on Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. TD Cowen lifted their price objective on shares of Roivant Sciences from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and an average price target of $40.62.

Insiders Place Their Bets

In other Roivant Sciences news, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the transaction, the insider owned 18,630,739 shares in the company, valued at $675,364,288.75. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. This represents a 11.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,055,913 shares of company stock worth $107,261,258 in the last 90 days. Company insiders own 8.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.